Matching articles for "GlucaGen Hypokit"
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The FDA has approved dasiglucagon ( Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be…
Med Lett Drugs Ther. 2021 Aug 23; 63(1631):132-4
The FDA has approved dasiglucagon ( Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require reconstitution before administration; Gvoke , a SC formulation approved for use in patients ≥2 years old, and Baqsimi , an intranasal powder approved for use in patients ≥4 years old, have been available since 2019. Injectable glucagon emergency kits ( GlucaGen HypoKit , and generics) have been available for years, but they require reconstitution of the lyophilized powder immediately before administration.
In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia
The FDA has approved a new formulation of glucagon ( Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of…
Med Lett Drugs Ther. 2019 Nov 18; 61(1585):186
The FDA has approved a new formulation of glucagon ( Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products ( Glucagon Emergency Kit , and others), Gvoke does not require reconstitution before administration. A glucagon nasal powder (Baqsimi) that does not require coordination with inhalation was recently approved for use in patients ≥4 years old.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The FDA has approved glucagon nasal powder ( Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become…
Med Lett Drugs Ther. 2019 Sep 23; 61(1581):148-9
The FDA has approved glucagon nasal powder ( Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits ( GlucaGen Hypokit , and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available later in 2019; it will be reviewed in a future issue.
